Private equity firm Gryphon Investors has signed a definitive agreement to acquire Revision Skincare and Goodier Cosmetics. In partnership with Revision Goodier’s leadership team, including CEO Maria Carell, Gryphon will continue to invest in the company’s mission of developing and delivering clinically-proven and highly-efficacious skin care products to a global customer base and advance the company’s contract development and manufacturing capabilities. Financial terms of the transaction were not disclosed. The transaction is expected to close in the fourth quarter of 2021.

Revision Skincare is sold globally in the professional distribution channel via dermatologists, plastic surgeons and medical spas. The company is based in Irving and was formulated to provide targeted solutions to enhancing skin’s appearance and reducing signs of aging. Goodier Cosmetics has been a developer and manufacturer in cosmetic and OTC topical skin care solutions. Differentiated by an industry renowned Innovation Center of Excellence, Goodier, along with its team of R&D chemists, engineers and regulatory experts, remains at the forefront of market trends, new technologies, ingredients and advancements in formulation science. The portfolio includes well-known franchises such as Nectifirm®, Intellishade®, D·E·J and Revox™.

Eddie Douglas, Principal in Gryphon’s Consumer Group, noted, “We are thrilled to partner with Maria and her outstanding team to support Revision’s movement to bring scientific credibility, quality, innovation, and elegance to the professional skin care market. We are equally excited about the opportunity to build on Goodier’s differentiated capabilities and deliver world-class service to some of the fastest growing brands across the prestige beauty and personal care space.”

Revision Goodier’s management team will continue to be led by CEO Maria Carell. As part of the transaction, a number of Gryphon Executive Advisors will join Gryphon Operating Partner Mike Ferry, Gryphon Deal Partner Matt Farron, and Gryphon Principal Eddie Douglas on the Board of Directors. The transaction marks Gryphon’s third investment in skin care products and services and first investment in the physician dispensed skin care category.

William Blair & Company, LLC is serving as the exclusive financial advisors to Gryphon. Financo Raymond James is serving as financial advisors to Revision Goodier. Kirkland & Ellis LLP is acting as legal advisor to Gryphon, and Sidley Austin LLP is acting as legal advisor to Revision Goodier.